LOGO.png
Autolus Therapeutics presents additional data on AUTO3 in DLBCL during the ESMO Virtual Congress 2020
September 18, 2020 03:05 ET | Autolus Therapeutics plc
-  AUTO3 shows promise of a highly differentiated product profile Conference call and webcast to be held Friday, September 18, 2020 at 8:00 am EDT / 1:00 pm BST LONDON, Sept. 18, 2020 (GLOBE...
LOGO.png
Autolus Therapeutics to host Investor Conference Call to discuss AUTO3 data presented at ESMO and to participate in Banking conferences through September
September 08, 2020 07:00 ET | Autolus Therapeutics plc
LONDON, Sept. 08, 2020 (GLOBE NEWSWIRE) -- Autolus Therapeutics plc (Nasdaq: AUTL), a clinical-stage biopharmaceutical company developing next-generation programmed T cell therapies, today announced...
LOGO.png
Autolus Therapeutics Reports Second Quarter 2020 Financial Results and Operational Progress
August 06, 2020 07:00 ET | Autolus Therapeutics plc
LONDON, Aug. 06, 2020 (GLOBE NEWSWIRE) -- Autolus Therapeutics plc (Nasdaq: AUTL), a clinical-stage biopharmaceutical company developing next-generation programmed T cell therapies, today announced...
LOGO.png
Autolus announces changes to its Board and Management Team
August 04, 2020 07:00 ET | Autolus Therapeutics plc
LONDON, Aug. 04, 2020 (GLOBE NEWSWIRE) -- Autolus Therapeutics plc (Nasdaq: AUTL), a clinical-stage biopharmaceutical company developing next-generation programmed T cell therapies, today announced...
LOGO.png
Autolus Therapeutics to Report Second Quarter 2020 Financial Results and Host Conference Call on August 6
July 30, 2020 07:00 ET | Autolus Therapeutics plc
LONDON, July 30, 2020 (GLOBE NEWSWIRE) -- Autolus Therapeutics plc (Nasdaq: AUTL), a clinical-stage biopharmaceutical company developing next-generation programmed T cell therapies, today announced...
LOGO.png
Autolus Therapeutics presents new preclinical data during the Virtual 2020 AACR Annual Meeting
June 22, 2020 07:00 ET | Autolus Therapeutics plc
- AUTO5 in T cell lymphoma – new in vitro and in vivo data presented demonstrating highly selective targeting of TRBC2 by a novel CAR T candidate - AUTO6NG in small cell lung cancer – in vitro and in...
LOGO.png
Autolus Therapeutics reschedules its investor EHA conference call
June 08, 2020 17:00 ET | Autolus Therapeutics plc
LONDON, June 08, 2020 (GLOBE NEWSWIRE) -- Autolus Therapeutics plc (Nasdaq: AUTL), a clinical-stage biopharmaceutical company developing next-generation programmed T cell therapies, today announced...
LOGO.png
Autolus Therapeutics presents additional data on AUTO3 in DLBCL during the ASCO20 Virtual Scientific Program
May 29, 2020 07:37 ET | Autolus Therapeutics plc
– Data continue to show encouraging clinical activity alongside tolerable safety to deliver a potentially highly differentiated product profile – Conference call and webcast to be held Monday, June...
LOGO.png
Autolus Therapeutics to host Investor Conference Calls through June
May 26, 2020 07:00 ET | Autolus Therapeutics plc
LONDON, May 26, 2020 (GLOBE NEWSWIRE) -- Autolus Therapeutics plc (Nasdaq: AUTL), a clinical-stage biopharmaceutical company developing next-generation programmed T cell therapies, today announced...
LOGO.png
Autolus Notice of Annual General Meeting (AGM) on Thursday, June 18, 2020
May 22, 2020 07:00 ET | Autolus Therapeutics plc
LONDON, May 22, 2020 (GLOBE NEWSWIRE) -- Autolus Therapeutics plc (Nasdaq: AUTL), a clinical-stage biopharmaceutical company developing next-generation programmed T cell therapies, today posted...